



# ESTABLISHED THERAPY FOR OCD



## EFFECTIVE CONTROL OF OBSESSIONS AND COMPULSIONS\*

### LOW INCIDENCE OF AGITATION

(2% vs 1% for placebo)<sup>1</sup>

### LOW INCIDENCE OF SEXUAL DYSFUNCTION<sup>1</sup>

- ❖ LUVOX® Tablets vs placebo<sup>†</sup>: decreased libido 2% vs 1%; delayed ejaculation 8% vs 1%; anorgasmia 2% vs 0%; impotence 2% vs 1%

### FAVORABLE SAFETY PROFILE

- ❖ Relatively low incidence of anticholinergic side effects in controlled trials of OCD and depression, LUVOX® Tablets vs placebo<sup>1</sup>: dizziness 11% vs 6%; constipation 10% vs 8%; dry mouth 14% vs 10%
- ❖ The most commonly observed adverse events compared to placebo were somnolence 22% vs 8%, insomnia 21% vs 10%, nervousness 12% vs 5%, nausea 40% vs 14%, abnormal ejaculation 8% vs 1%, asthenia 14% vs 6%<sup>1</sup>
- ❖ Concomitant use of LUVOX® Tablets and monoamine oxidase inhibitors is not recommended<sup>1</sup>

### FLEXIBLE DOSING

**Initial Dose: 50 mg once a day HS**

**Dose Range: 100 to 300 mg/day**

### COMPREHENSIVE SAFETY DATABASE

(Worldwide Exposure for Reporting Overdose<sup>‡</sup>)<sup>1</sup>

- ❖ Data from 40 countries
- ❖ Over 12 million patients treated
- ❖ More than 37,000 patients studied in clinical trials

**LUVOX®**  
fluvoxamine maleate 50 mg & 100 mg  
SCORED TABLETS

**A SELECTIVE SEROTONIN  
REUPTAKE INHIBITOR**

\*Effectiveness not established beyond 10 weeks in controlled trials.

<sup>†</sup>Parameters occurring ≥ 1% with fluvoxamine maleate.

<sup>‡</sup>Prescribers should write the smallest tablet quantity consistent with good patient management to reduce overdose risk.

Please see brief summary of prescribing information on adjacent page.